BioElectronics Corporation (OTC: BIEL) announced today the imminent commercial launch of ActiPatch in Taiwan through its appointed distributor, Aphrodite Medical Group. The move marks a significant step in expanding access to drug-free, bioelectronic pain therapy in the Asian market, challenging traditional pharmaceutical approaches to pain management.
ActiPatch is a US FDA-cleared, non-invasive medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and is designed for extended wear, including during sleep, offering a practical alternative to pharmaceuticals for patients seeking pain relief without drugs or side effects.
“The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan,” said Kelly Whelan, CEO of BioElectronics Corporation. “Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way.” The initial shipment of ActiPatch units has been completed, positioning the product for a coordinated market launch in Q2 2026, with a focus on musculoskeletal pain management.
Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels. Yang Pei-Hsien, Vice President of Aphrodite Medical Group, stated, “We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies. This technology aligns with the growing demand for safe, effective, and drug-free pain management options.”
The launch reinforces BioElectronics’ strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. The company’s product portfolio includes ActiPatch and RecoveryRx, both FDA-cleared devices using pulsed shortwave technology to treat pain and support recovery.
This expansion into Taiwan comes amid rising global concerns over opioid dependency and side effects of long-term pain medication use, positioning ActiPatch as a viable non-pharmacological option. The initial rollout targets musculoskeletal conditions, with opportunities for expansion across additional clinical applications over time, potentially impacting how pain is managed in clinical settings across the region.
For more information, visit the original release on NewMediaWire.
